Sign in

CIK 0001498382

  • Non-accelerated filer
  • Smaller reporting company

TuHURA Biosciences, Inc./NV

Sign in to watch
Ticker
HURA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
NV
Entity type
Operating
EIN
990360497
Phone
+1 813-875-6600
Business address
10500 UNIVERSITY CENTER DR., SUITE 110, TAMPA, FL, 33612
Former names
Kintara Therapeutics, Inc., DelMar Pharmaceuticals, Inc., Berry Only Inc.
  1. 3 Insider Initial Statement of Ownership
  2. 4 Open-market buy CEO and President bought 7,500 shares at an average $0.66 ($4,925)
  3. 4 Open-market buy CEO and President bought 2,500 shares at $0.90 ($2,250)
  4. 4 Open-market buy CEO and President bought 2,500 shares at $0.92 ($2,300)
  5. 4 Open-market buy Director bought 8,000 shares at $0.95 ($7,600)
  6. 4/A Derivatives Options or other derivatives
  7. 3/A Insider 3/A
  8. 4 Conversion Director acquired 2,388,541 shares (conversion)
  9. 4 Other acquisition Chief Scientific Officer acquired 278,530 shares (other)
  10. 4 Open-market buy CEO and President bought 4,000 shares at $0.98 ($3,920)
  11. 3/A Insider 3/A
  12. 4 Open-market buy CEO and President bought 4,985 shares at $0.75 ($3,739)
  13. 4 Open-market buy Director bought 7,000 shares at $0.71 ($4,970)
  14. 4 Open-market buy Director bought 8,000 shares at $0.78 ($6,237)
  15. 4 Open-market buy Director bought 20,000 shares at $1.25 ($25,000)
  16. 4 Open-market buy CEO and President bought 10,000 shares at $1.30 ($13,000)
  17. 4 Open-market buy Director bought 25,000 shares at $1.30 ($32,500)
  18. 4 Open-market sale Director sold 80,000 shares at $1.30 ($104,000)
  19. 4 Open-market buy Director bought 25,000 shares at $1.30 ($32,500)
  20. 4 Open-market buy CFO bought 10,000 shares at $1.30 ($13,000)

Page 14 of 16 · 308 filings